552c7ae14ClaimThe metabolic health benefits of GLP-1 drugs outweigh their dermatological side effectsAgreeDisagree
552c7ae14ClaimThe FDA drug recall system catches contamination issues before they reach patientsAgreeDisagree
552c7ae14ClaimPharmaceutical manufacturing quality standards are sufficient to prevent particulate contaminationAgreeDisagree
552c7ae14ClaimThe FDA also announced multiple food recalls in October 2026 including Listeria-contaminated smoked salmon and Salmonella-contaminated broccoli seeds.AgreeDisagree
552c7ae14ClaimThe recall was conducted with the knowledge of the U.S. Food and Drug Administration.AgreeDisagree
552c7ae14ClaimArgatroban is a direct thrombin inhibitor indicated for prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia and as an anticoagulant in percutaneous coronary intervention.AgreeDisagree
552c7ae14ClaimTo date, Par Health has not received any reports of adverse events related to this recall.AgreeDisagree
552c7ae14ClaimAdministration of Argatroban Injection containing particulate matter could cause life-threatening adverse health consequences including pulmonary emboli, blood vessel occlusions, and vein inflammation leading to clotting.AgreeDisagree
552c7ae14ClaimPar Health USA recalled 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) due to the presence of particulate matter including cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel.AgreeDisagree
552c7ae14ClaimThe recall is being conducted to the hospital and user level, with Par Health arranging for return of all existing inventory through Inmar, Inc.AgreeDisagree
552c7ae14ClaimAdverse reactions can be reported to the FDA MedWatch Adverse Event Reporting program online, by regular mail, or by fax.AgreeDisagree
552c7ae14ClaimPlacebo-controlled trials should be required before approving new medicinesAgreeDisagree
552c7ae14ClaimNew medicines should have to outperform existing treatments before approvalAgreeDisagree
552c7ae14ClaimDrugs for serious illnesses should qualify for accelerated approval based on biomarkers before patient benefit is provenAgreeDisagree
552c7ae14ClaimTerminally ill patients should be allowed experimental drugs before trials establish effectivenessAgreeDisagree
552c7ae14ClaimAdults should be allowed attention-enhancing drugs even without a medical disorderAgreeDisagree
552c7ae14ClaimGLP-1 manufacturers bear liability for not warning US patients about NAIONAgreeDisagree